Search

Deadlines & Announcements

New announcements will be published as soon as new elements for the Congress Sponsor Program for EHA2025 are released.

Read more

Advances from genome sequencing are paving the way to personalized treatment for leukemia and pre-leukemia

In acute myeloid leukemia (AML) our understanding of how modifications to DNA molecules that do not result in sequence change (i. e.

Read more

Advocacy priorities

The European Union works on countless pieces of legislation and policies that affect the health ecosystem. Some are relevant to most medical disciplines, including hematology—such as the legislation on health data or pharmaceuticals.

Read more

A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER!

A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER!

We recently discovered a new form of an inherited deficiency of platelets (inherited thrombocytopenia-IT), which is caused by mutations in the ETV6-gene.

Read more

Meet Antonio Almeida, our February Volunteer of the Month

EHA is a Public Benefit Organization under Dutch law.

Read more

Meet Antonio Almeida, our February Volunteer of the Month

EHA is a Public Benefit Organization under Dutch law.

Read more

Gdf -11 a new target to improve anemia in thalassemia.

 

β-thalassemias are characterized by ineffective red blood cell (RBC) production, leading to anemia, iron overload, and organ failure. As current treatment options for β-thalassemia are limited, there is a clear unmet need for alternative therapies.

Read more